Adarsh Subbaswamy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adarsh Subbaswamy has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Allison Dunn
Center for Translational Medicine University of Maryland School of Pharmacy Baltimore MD USA
1 shared publication Berkman Sahiner
Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, USA
1 shared publication- Brooke Langevin
Center for Translational Medicine University of Maryland School of Pharmacy Baltimore Maryland USA
1 shared publication - Jogarao V. S. Gobburu
Center for Translational Medicine University of Maryland School of Pharmacy Baltimore MD USA
1 shared publication - Mathangi Gopalakrishnan
Center for Translational Medicine University of Maryland School of Pharmacy Baltimore Maryland USA
1 shared publication Matthew C. Diamond
Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, USA
1 shared publication
Latest Publications
- Open Access
- 19 May 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (6) , e70617
From Precision to Personalized: Catalyzing AI ‐Enabled Innovation in Drug Development
In 2015, President Obama announced the Precision Medicine Initiative in his nationally televised State of the Union address. The vision was bold: to enable a new era of medicine through research, technology, and policies that empower patients, researchers, and providers to work together toward the development of individualized care. Now, more than 10 years later, how have the treatments available to patients changed?
- 19 May 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (6) , e70617
Open AccessFrom Precision to Personalized: Catalyzing AI ‐Enabled Innovation in Drug Development
In 2015, President Obama announced the Precision Medicine Initiative in his nationally televised State of the Union address. The vision was bold: to enable a new era of medicine through research, technology, and policies that empower patients, researchers, and providers to work together toward the development of individualized care. Now, more than 10 years later, how have the treatments available to patients changed?
- Open Access
- 21 November 2024
- Published by Springer Nature in npj Digital Medicine
- Vol. 7 (1) , 1-11
A data-driven framework for identifying patient subgroups on which an AI/machine learning model may underperform
A fundamental goal of evaluating the performance of a clinical model is to ensure it performs well across a diverse intended patient population. A primary challenge is that the data used in model development and testing often consist of many overlapping, heterogeneous patient subgroups that may not be explicitly defined or labeled. While a model’s average performance on a dataset may be high, the model can have significantly lower performance for certain subgroups, which may be hard to detect. We describe an algorithmic framework for identifying subgroups with potential performance disparities (AFISP), which produces a set of interpretable phenotypes corresponding to subgroups for which the model’s performance may be relatively lower. This could allow model evaluators, including developers and users, to identify possible failure modes prior to wide-scale deployment. We illustrate the application of AFISP by applying it to a patient deterioration model to detect significant subgroup performance disparities, and show that AFISP is significantly more scalable than existing algorithmic approaches.
- 21 November 2024
- Published by Springer Nature in npj Digital Medicine
- Vol. 7 (1) , 1-11
Open AccessA data-driven framework for identifying patient subgroups on which an AI/machine learning model may underperform
A fundamental goal of evaluating the performance of a clinical model is to ensure it performs well across a diverse intended patient population. A primary challenge is that the data used in model development and testing often consist of many overlapping, heterogeneous patient subgroups that may not be explicitly defined or labeled. While a model’s average performance on a dataset may be high, the model can have significantly lower performance for certain subgroups, which may be hard to detect. We describe an algorithmic framework for identifying subgroups with potential performance disparities (AFISP), which produces a set of interpretable phenotypes corresponding to subgroups for which the model’s performance may be relatively lower. This could allow model evaluators, including developers and users, to identify possible failure modes prior to wide-scale deployment. We illustrate the application of AFISP by applying it to a patient deterioration model to detect significant subgroup performance disparities, and show that AFISP is significantly more scalable than existing algorithmic approaches.